[go: up one dir, main page]

AU2002214223A1 - Long-acting cytokine derivatives and pharmaceutical compositions comprising them - Google Patents

Long-acting cytokine derivatives and pharmaceutical compositions comprising them

Info

Publication number
AU2002214223A1
AU2002214223A1 AU2002214223A AU1422302A AU2002214223A1 AU 2002214223 A1 AU2002214223 A1 AU 2002214223A1 AU 2002214223 A AU2002214223 A AU 2002214223A AU 1422302 A AU1422302 A AU 1422302A AU 2002214223 A1 AU2002214223 A1 AU 2002214223A1
Authority
AU
Australia
Prior art keywords
cytokine
pharmaceutical compositions
derivatives
fluorenylmethoxycarbonyl
fms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214223A
Inventor
Matityahu Fridkin
Itzhak Goldwaser
Yoram Shechter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU2002214223A1 publication Critical patent/AU2002214223A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Cytokine derivatives are provided bearing functional groups sensitive to mild basic conditions such as fluorenylmethoxycarbonyl (Fmoc) and 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) and pharmaceutical compositions comprising them. Preferred derivates are those in which amino groups of the cytokine are substituted with FMS, for example FMS7-IFN- alpha 2 and FMS3-IL-2. These cytokine derivatives can be administered as inactive or slightly active prodrugs and are capable of undergoing spontaneous regeneration into the parent bioactive drugs under <i>in vivo physiological conditions and in a hom egenous fashion. The cytokine prodrugs present higher metabolic stability and augmented bioavailability.
AU2002214223A 2000-11-01 2001-10-30 Long-acting cytokine derivatives and pharmaceutical compositions comprising them Abandoned AU2002214223A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13940000A IL139400A0 (en) 2000-11-01 2000-11-01 Long-acting cytokine derivatives and pharmaceutical compositions comprising them
IL139400 2000-11-01
PCT/IL2001/001005 WO2002036067A2 (en) 2000-11-01 2001-10-30 Long-acting cytokine derivatives and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
AU2002214223A1 true AU2002214223A1 (en) 2002-05-15

Family

ID=11074784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214223A Abandoned AU2002214223A1 (en) 2000-11-01 2001-10-30 Long-acting cytokine derivatives and pharmaceutical compositions comprising them

Country Status (7)

Country Link
US (1) US20040131586A1 (en)
EP (1) EP1337270B1 (en)
AT (1) ATE401098T1 (en)
AU (1) AU2002214223A1 (en)
DE (1) DE60134883D1 (en)
IL (2) IL139400A0 (en)
WO (1) WO2002036067A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1620118T3 (en) * 2003-04-08 2014-11-28 Yeda Res & Dev Reversible pegylated drugs
AU2006259225B2 (en) 2005-06-16 2012-05-31 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
WO2011013128A2 (en) 2009-07-31 2011-02-03 Yeda Research And Development Co. Ltd. Vectors for delivery of neurotherapeutics to the central nervous system
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
CN104684576B (en) 2012-06-04 2019-08-06 奥普科生物制品有限公司 PEGylated OXM variants
CN106554296A (en) * 2015-09-30 2017-04-05 深圳翰宇药业股份有限公司 A kind of Fmoc(SO with excellent hydrophilic3H) amino acid of protection and preparation method thereof
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
CN117551008B (en) * 2023-11-10 2025-10-17 沈阳药科大学 Deferoxamine conjugate and preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them

Also Published As

Publication number Publication date
ATE401098T1 (en) 2008-08-15
EP1337270A2 (en) 2003-08-27
IL139400A0 (en) 2001-11-25
EP1337270B1 (en) 2008-07-16
IL155656A (en) 2010-02-17
DE60134883D1 (en) 2008-08-28
WO2002036067A2 (en) 2002-05-10
WO2002036067A3 (en) 2003-01-09
EP1337270A4 (en) 2005-09-14
US20040131586A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
EP0693924A4 (en) METHODS FOR -i(IN VIVO) DELIVERY OF BIOLOGICS AND COMPOSITIONS USEFUL THEREFOR
SI0991407T2 (en) Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations
AP1760A (en) Platinum derivative pharmaceutical formulations.
AU2724292A (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-d-neuraminic acid
EP1589947B8 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
AU1416501A (en) Novel phenylalanine derivatives
SV2004001556A (en) ACID PREPARATIONS OF INSULIN WITH IMPROVED STABILITY
TR199801861T2 (en) Pharmaceutically useful compositions.
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
CA2356959A1 (en) Water-insoluble drug delivery system
AU2002214223A1 (en) Long-acting cytokine derivatives and pharmaceutical compositions comprising them
AU3756797A (en) Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance
WO2003092655A3 (en) Use of active ingredient mixtures with azelaic acids and glycyrrhetic acids as anti-acne agents
WO1999012545A3 (en) Medicaments containing acyclovir
CA2386423A1 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines c
AU9270598A (en) Hydrazono-benzazulene derivatives, pharmaceutical compositions and in termediates
AU3739500A (en) Protease resistant flint analogs
AP9901659A0 (en) Quinoline-2-carboxylic acid derivatives and its use as excitatory amino acids antagonist.
EA200200415A1 (en) COMPOSITION OF PHARMACEUTICAL MEDIA
AU2003224107A1 (en) Soluble composition containing sporopollenin and the use thereof
RU94040865A (en) Peptide derivatives and therapeutically acceptable salts thereof, process for preparation thereof, pharmaceutical composition having antiviral activity
ITMI20020872A1 (en) HYPERPHORINE DERIVATIVES THEIR USE AND FORMULATIONS CONTAINING THEM
ATE252598T1 (en) STREPTOGRAMINE DERIVATIVES, THEIR PRODUCTION AND PREPARATIONS CONTAINING THEM
AU2002355691A1 (en) Pharmaceutical preparations containing aminobenzene- sulfonic acid derivatives as the active ingredient
UA64074C2 (en) Cardioprotective antioxidant drug &#34;elgacin&#34;